The development of a liposomal form Secukinumab – an IL 17 pathway inhibitor in the treatment of psoriasis
type: CreativeWork
description: Various approaches are currently used to treat and manage psoriasis, and biological treatments are often the latest approaches. All biological treatments have major side effects as they are given systemically via injections. One of the latest biological treatments for psoriasis, one which has shown great efficacy with fewer side effects, is Secukinumab. Secukinumab is an anti-IL17 antibody that works by stopping the action of IL17, a cytokine that is known to have a major role in the pathogenesis of psoriasis. This work is based on the development of a new way to commence drug therapy to reduce the side effects of the treatment. Our work is based on the studies of the genotoxicity of the drug Secukinumab in its bulk and liposome form using comet and micronucleus assays on lymphocytes. The results from both assays have illustrated the safety of the drug and demonstrated the reduction of the DNA damage induced in both healthy individuals and patients with psoriasis. Secukinumab significantly decreases-H2O2 induced damage and efficiently attenuates its adverse effects both in the comet (p<0.0001) and micronucleus assays (p<0.01). The two concentrations of Secukinumab used (2.1 and 2.8μg/ml) efficiently decreased H2O2-induced DNA damage in both groups to nearly the level of the negative control. Overall, Secukinumab reveals protective and anti-genotoxic effects by demonstrating its potential in reducing DNA damage caused by oxidative stress and by not inducing any further damage in the lymphocytes of either healthy individuals or patients. Liposomes are highly versatile which have been proven efficient for therapy and research applications. The discovery of new therapies in the treatment of psoriasis is a considerable challenge and is now a necessity. Our study was the first one to determine the genotoxicity of various concentrations of the drug in the lymphocytes of psoriasis patients compared to healthy individuals. In the MTT assay, the data showed a decrease in % ce…
abstract: Various approaches are currently used to treat and manage psoriasis, and biological treatments are often the latest approaches. All biological treatments have major side effects as they are given systemically via injections. One of the latest biological treatments for psoriasis, one which has shown great efficacy with fewer side effects, is Secukinumab. Secukinumab is an anti-IL17 antibody that works by stopping the action of IL17, a cytokine that is known to have a major role in the pathogenesis of psoriasis. This work is based on the development of a new way to commence drug therapy to reduce the side effects of the treatment. Our work is based on the studies of the genotoxicity of the drug Secukinumab in its bulk and liposome form using comet and micronucleus assays on lymphocytes. The results from both assays have illustrated the safety of the drug and demonstrated the reduction of the DNA damage induced in both healthy individuals and patients with psoriasis. Secukinumab significantly decreases-H2O2 induced damage and efficiently attenuates its adverse effects both in the comet (p<0.0001) and micronucleus assays (p<0.01). The two concentrations of Secukinumab used (2.1 and 2.8μg/ml) efficiently decreased H2O2-induced DNA damage in both groups to nearly the level of the negative control. Overall, Secukinumab reveals protective and anti-genotoxic effects by demonstrating its potential in reducing DNA damage caused by oxidative stress and by not inducing any further damage in the lymphocytes of either healthy individuals or patients. Liposomes are highly versatile which have been proven efficient for therapy and research applications. The discovery of new therapies in the treatment of psoriasis is a considerable challenge and is now a necessity. Our study was the first one to determine the genotoxicity of various concentrations of the drug in the lymphocytes of psoriasis patients compared to healthy individuals. In the MTT assay, the data showed a decrease in % ce…
author: Layas, Gazala I.
language: en
keywords: Secukinumab, Liposomes, Geno-protective, Lymphocytes, Psoriasis, Comet, MN assay, Oxidative stress, Genotoxicity
date published: 2022
date modified: 2026-07-24T01:14:08Z
provider: University of Bradford
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: University of Bradford